MARIPOSA
30 Nov 2021
MARIPOSA
NCT04487080
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Janssen Research & Development, LLC
Cancer Type | Lung & mesothelioma |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2020-09-30 |
Anticipated End Date | 2024-04-30 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Dr Shawgi Sukumaran |
Recruitment Status | Closed |
Keep up to date with the latest news and breakthroughs